Navigation Links
InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
Date:2/8/2010

LOS ALTOS, Calif., Feb. 8 /PRNewswire/ -- InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.

Dr. Mantzoros is a member of Harvard's Division of Endocrinology, Diabetes, and Metabolism, and is an acknowledged expert in the fields of insulin resistance, body weight regulation, adipokine biology, and energy homeostasis. He has published more than 200 original papers and more than 100 reviews and chapters which have received more than 12,000 citations. He has received several national and international awards and has also been elected a member of The American Society for Clinical Investigation (ASCI).

Dr. Mantzoros, who trained at Harvard, serves as Founding Director of the Human Nutrition Research Unit and as the Clinical Research Overseer at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center. In conjunction with his new appointment, he will also be assuming responsibilities as Chief of Endocrinology and Diabetes at the Greater Boston VA Healthcare System, a system of three hospitals and six outpatient clinics in the greater Boston area which are affiliated with Harvard Medical School.

Dennis M. Lanfear, President and Chief Executive Officer, and Dr. Mantzoros founded InteKrin Therapeutics Inc in 2005. Dr. Mantzoros remains an integral part of InteKrin Therapeutics' management team and regularly advises on scientific matters.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc


'/>"/>
SOURCE InteKrin Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
2. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
5. BioMarin to Acquire LEAD Therapeutics
6. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
9. Pepscan Therapeutics Strengthens Management Team
10. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
11. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):